Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: SHP465
DRUG: Placebo

Sponsor

Shire